TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04259138

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Treatment Algorithm C
Description: Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Treatment Algorithm C
Description: Participants who are taking a TNFα antagonist (infliximab, golimumab, or adalimumab), tofacitinib, or ustekinumab therapy at screening will follow the treatment algorithm.~Participants will change to intravenous vedolizumab therapy.~Participants will be assessed to determine it remission target is achieved at weeks 16, 32 and 48. If the participant has achieved their treatment target, they will continue that line of therapy. If the participant has not achieved their treatment target, treatment and/or dose escalation will be administered according to the algorithm.
Study: NCT03186703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored knowledge translation
Description: Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
Study: NCT00551382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muntelukast
Description: Tablets or granules; 4 mg once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Look alike tablets or granules 1 per day for 12 weeks
Study: NCT03852459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Ibuprofen
Description: Topical Gel 5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Gel
Study: NCT01725919

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CI therapy
Description: constraint induced movement therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CI therapy
Description: constraint induced movement therapy
Study: NCT01565772

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation
Description: 45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
Study: NCT01061151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])
Description: 200 mg/300 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine (NVP): Infant short-course
Description: Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.
Study: NCT01565772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg/m2 IV on days 1, 8 of cycles 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 50 mg/m2 IV on days 1-5 on Cycles 1-2
Study: NCT01061151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP): Infant short-course
Description: Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP): Infant short-course
Description: Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP): Infant short-course
Description: Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP): Infant extended
Description: Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Women registered before/during labor received the full Antepartum Arm A regimen.~Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada \[TRV\]) tail.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discontinue triple ARVs
Description: ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continue triple ARVs
Description: Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).
Study: NCT01684150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPZ-5676
Description: MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
Study: NCT04207294

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pork arm
Description: The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pork arm
Description: The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pork arm
Description: The effect of 1 portion of vitamin D-enriched pork on 25(OH)D concentration in comparison to a vitamin D supplement and control pork.
Study: NCT01720030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Verum therapy
Study: NCT04207294

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chicken arm
Description: The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chicken arm
Description: The effect of 1 portion of vitamin D-enriched chicken on 25(OH)D concentration in comparison to control chicken.
Study: NCT02082548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
Study: NCT00827346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600 mg now

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600 mg now and 600 mg in 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 900 mg now

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 600 mg now and 300 mg in 3 hours
Study: NCT02019524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E39 peptide vaccine
Description: 500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the E39 peptide vaccine. For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E39 vaccine then J65 vaccine
Description: The E39 vaccine is prepared as noted above. For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the J65 vaccine. For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: J65 vaccine then E39 vaccine
Description: The E39 and J65 vaccines are prepared as noted above. For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
Study: NCT02542917

Intervention type: DEVICE
Intervention: IBDoc home test for faecal calprotectin
Description: IBDoc home test for faecal calprotectin
Study: NCT04416126

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-810
Description: ARCT-810 is an investigational medicinal product comprising OTC mRNA formulated in a lipid nanoparticle (LNP) under development.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo for this study is 0.9% sterile saline.
Study: NCT02737735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard chemotherapy medicine combined with Chinese herbs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemotherapy medicine
Study: NCT01720030

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Conventional therapy
Description: Placebo therapy to safeguard blinding
Study: NCT03793621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357
Description: single rising oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single rising oral dose
Study: NCT03961906

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: Will receive two trainings. First training in week one after baseline assessment for three consecutive days 60 min twice daily by trained physiotherapists and in week three further two days with 60min once daily.
Study: NCT00602693

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Description: Infusion of umbilical cord blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.
Study: NCT02709083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Given orally
Study: NCT02525419

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight Loss Phase
Description: High Protein, Intermittent Fast, Low Calorie Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HP-IF
Description: High Protein, Intermittent Fast

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HH
Description: Heart Healthy
Study: NCT01844830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: Intranasally administered regional anesthetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredients supplied in identical nasal sprayer
Study: NCT02327221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovasave
Description: During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovasave
Description: During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovasave
Description: During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
Study: NCT02170649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Study: NCT02500602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxazosin
Description: active medication

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pill
Study: NCT01319786

Intervention type: OTHER
Group type: OTHER
Intervention: Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
Description: Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
Study: NCT00602693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 40 mg/m\^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2
Study: NCT00996021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 250 mg
Description: This is an experimental HIV medication in the integrase inhibitor class.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Suspension
Description: Placebo is a liquid with no drug in it.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: This is an FDA approved antibiotic in the fluoroquinolone class.
Study: NCT04385615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: Participants will be requested to follow three cycles (of 5 day each), for three consecutive months, of a Fasting Mimicking Diet, a plant-based, low-calorie, low-protein, low-carbohydrate, high-unsaturated fat diet. For the remaining 25 days of each month, participants should continue with their habitual eating habits.
Study: NCT01319786

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
Description: Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
Study: NCT04486755

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: All patients RT will be delivered utilizing pencil beam scanning proton therapy. Radiation treatment will be delivered 4 days per week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: All patients RT will be delivered utilizing pencil beam scanning proton therapy. Radiation treatment will be delivered 4 days per week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: All patients RT will be delivered utilizing pencil beam scanning proton therapy. Radiation treatment will be delivered 4 days per week.
Study: NCT02341833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
Study: NCT01157897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VMP001
Description: Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VMP001
Description: Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VMP001
Description: Plasmodium vivax malaria protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P. vivax sporozoite challenge
Description: P. vivax sporozoite challenge
Study: NCT00602693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg intravenous over 2 hours on Day -6

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 200 cGy on Day -1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Treg infusion
Description: Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10\^5 Treg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.
Study: NCT01157897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P. vivax sporozoite challenge
Description: P. vivax sporozoite challenge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P. vivax sporozoite challenge
Description: P. vivax sporozoite challenge
Study: NCT00419692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.
Study: NCT03568747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: noninvasive ventilation
Description: dual-limb circuit NIV were given on maquet servo i apparatus

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen therapy
Description: oxygen therapy were introduced to the side port of the facemask
Study: NCT02474979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBPM-system
Description: The bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Study: NCT03059784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP-based multifaceted management
Description: Patients after PCI will be regularly given education materials, medication reminders, life-style behaviors instruction through APP. Cardiologists can interact with patients on advice provision and clinical support after discharge through APP.
Study: NCT01157897

Intervention type: OTHER
Group type: OTHER
Intervention: P. vivax sporozoite challenge
Description: P. vivax sporozoite challenge
Study: NCT03433716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Percutaneous Neuromodulation
Description: It's a new intervention of sport physiotherapy. It´s an invasive technique. It is necessary an ultrasound
Study: NCT01709279

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: adipose tissue derived stromal cells dosage
Description: intra-coronary administration of autologous adipose tissue derived stroma cells
Study: NCT04153019

Intervention type: OTHER
Group type: OTHER
Intervention: Psychoeducational and rehabilitative intervention
Description: Psycho-educational session: 3 weekly face-to-face consultations between a dyads and trained nurses, helping them to cope with cancer cachexia strengthening dyadic coping resources; 2) Rehabilitation program: 3 sessions with physiotherapists including educational component for patients self-management on physical activity and goal-setting, personalized program of exercises stretching and relaxation + 3 home sessions per week, self-managed by dyads.
Study: NCT02769884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MMPPC algorithm artificial pancreas
Description: An artificial pancreas system using the MMPPC algorithm, Roche insulin pump, and Dexcom CGM
Study: NCT00195013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glutamine
Description: 10 grams three times a day (orally) for four days and then stop

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 grams three times a day (orally) for four days and then stop